Page last updated: 2024-11-04

sarpogrelate and Diabetes Mellitus, Type 2

sarpogrelate has been researched along with Diabetes Mellitus, Type 2 in 13 studies

sarpogrelate: structure given in first source

Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.

Research Excerpts

ExcerptRelevanceReference
"The results of the Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS), a randomized double-blind study of sarpogrelate (selective 5-HT(2A) receptor antagonist) versus aspirin in 1510 Japanese patients, have been reported."9.14Sarpogrelate versus aspirin in secondary prevention of cerebral infarction: differential efficacy in diabetes? Subgroup analysis from S-ACCESS. ( Nishimaru, K; Shinohara, Y, 2009)
"Forty patients who had diabetes with nephropathy and arteriosclerosis obliterans and had already been treated with angiotensin II receptor blocker (n = 40) were randomly assigned to sarpogrelate (300 mg/d; n = 20) or aspirin group (100 mg/d; n = 20)."9.13Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes. ( Ishizuka, T; Ito, S; Mori, T; Nako, K; Ogawa, S, 2008)
" We then investigated the effects of 24-month treatment with sarpogrelate hydrochloride, a 5-HT(A2) receptor antagonist, on urinary albumin level in 10 type 2 diabetics with microalbuminuria, compared with not treated control group."9.10Sarpogrelate hydrochloride, a serotonin2A receptor antagonist, reduces albuminuria in diabetic patients with early-stage diabetic nephropathy. ( Haraguchi, T; Higashi, K; Kobori, S; Koga, N; Minami, J; Takahashi, T; Yano, M, 2002)
" Acute and chronic effects of sarpogrelate hydrochloride (sarpogrelate), a 5-HT2 blocker, on glucose tolerance and insulin resistance were examined."7.72Effect of sarpogrelate hydrochloride, a 5-HT2 blocker, on insulin resistance in Otsuka Long-Evans Tokushima fatty rats (OLETF rats), a type 2 diabetic rat model. ( Harada, N; Nakaya, Y; Takahashi, A; Takishita, E; Yamato, M; Yoshizumi, M, 2004)
"The aim was to evaluate the significance of arteriosclerosis obliterans-related biomarkers in patients with type 2 diabetes mellitus (T2DM), and to compare the effects of sarpogrelate, eicosapentaenoic acid (EPA) and pitavastatin on these markers."5.27Effects of sarpogrelate, eicosapentaenoic acid and pitavastatin on arterioslcerosis obliterans-related biomarkers in patients with type 2 diabetes (SAREPITASO study). ( Ito, T; Nomura, S; Okuda, Y; Omoto, S; Shouzu, A; Suzuki, M; Taniura, T, 2018)
"8 years with 10-75% coronary artery stenosis, as assessed by coronary computed tomography angiography, were randomly assigned to sarpogrelate 300 mg/day plus aspirin 100 mg/day (SPG + ASA group) or aspirin 100 mg/day alone (ASA group) for 6 months."5.24Effect of sarpogrelate, a selective 5-HT ( Chun, EJ; Han, SJ; Hur, JH; Jang, HC; Kang, DK; Kim, HJ; Kim, KM; Lee, DH; Lee, JE; Lim, S; Min, SH; Oh, TJ, 2017)
"The results of the Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS), a randomized double-blind study of sarpogrelate (selective 5-HT(2A) receptor antagonist) versus aspirin in 1510 Japanese patients, have been reported."5.14Sarpogrelate versus aspirin in secondary prevention of cerebral infarction: differential efficacy in diabetes? Subgroup analysis from S-ACCESS. ( Nishimaru, K; Shinohara, Y, 2009)
"Forty patients who had diabetes with nephropathy and arteriosclerosis obliterans and had already been treated with angiotensin II receptor blocker (n = 40) were randomly assigned to sarpogrelate (300 mg/d; n = 20) or aspirin group (100 mg/d; n = 20)."5.13Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes. ( Ishizuka, T; Ito, S; Mori, T; Nako, K; Ogawa, S, 2008)
" We then investigated the effects of 24-month treatment with sarpogrelate hydrochloride, a 5-HT(A2) receptor antagonist, on urinary albumin level in 10 type 2 diabetics with microalbuminuria, compared with not treated control group."5.10Sarpogrelate hydrochloride, a serotonin2A receptor antagonist, reduces albuminuria in diabetic patients with early-stage diabetic nephropathy. ( Haraguchi, T; Higashi, K; Kobori, S; Koga, N; Minami, J; Takahashi, T; Yano, M, 2002)
" Acute and chronic effects of sarpogrelate hydrochloride (sarpogrelate), a 5-HT2 blocker, on glucose tolerance and insulin resistance were examined."3.72Effect of sarpogrelate hydrochloride, a 5-HT2 blocker, on insulin resistance in Otsuka Long-Evans Tokushima fatty rats (OLETF rats), a type 2 diabetic rat model. ( Harada, N; Nakaya, Y; Takahashi, A; Takishita, E; Yamato, M; Yoshizumi, M, 2004)

Research

Studies (13)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (7.69)18.2507
2000's7 (53.85)29.6817
2010's5 (38.46)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Nomura, S2
Taniura, T1
Shouzu, A2
Omoto, S2
Suzuki, M1
Okuda, Y1
Ito, T1
Yoo, H1
Park, I1
Kim, DJ1
Lee, S1
Nagayama, D1
Ohira, M1
Saiki, A1
Shirai, K1
Tatsuno, I1
Lee, DH1
Chun, EJ1
Hur, JH1
Min, SH1
Lee, JE1
Oh, TJ1
Kim, KM1
Jang, HC1
Han, SJ1
Kang, DK1
Kim, HJ1
Lim, S1
Shinohara, Y1
Nishimaru, K1
Iizuka, K1
Hamaue, N1
Machida, T1
Hirafuji, M1
Tsuji, M1
Park, SY1
Rhee, SY1
Oh, S1
Kwon, HS1
Cha, BY1
Lee, HJ1
Lee, HC1
Kim, YS1
Takahashi, T2
Yano, M1
Minami, J1
Haraguchi, T1
Koga, N1
Higashi, K1
Kobori, S1
Yamakawa, J1
Itoh, T1
Kusaka, K1
Kawaura, K1
Wang, XQ1
Kanda, T1
Takishita, E1
Takahashi, A1
Harada, N1
Yamato, M1
Yoshizumi, M1
Nakaya, Y1
Nishikawa, M1
Iwasaka, T1
Ogawa, S1
Mori, T1
Nako, K1
Ishizuka, T1
Ito, S1
Pietraszek, MH1
Takada, Y1
Taminato, A1
Yoshimi, T1
Watanabe, I1
Takada, A1

Trials

7 trials available for sarpogrelate and Diabetes Mellitus, Type 2

ArticleYear
Effects of sarpogrelate, eicosapentaenoic acid and pitavastatin on arterioslcerosis obliterans-related biomarkers in patients with type 2 diabetes (SAREPITASO study).
    Vascular health and risk management, 2018, Volume: 14

    Topics: Adiponectin; Aged; Aged, 80 and over; Ankle Brachial Index; Arteriosclerosis Obliterans; Biomarkers;

2018
Effect of sarpogrelate, a selective 5-HT
    Atherosclerosis, 2017, Volume: 257

    Topics: Adult; Aged; Ankle Brachial Index; Anti-Inflammatory Agents; Aspirin; Biomarkers; Computed Tomograph

2017
Sarpogrelate versus aspirin in secondary prevention of cerebral infarction: differential efficacy in diabetes? Subgroup analysis from S-ACCESS.
    Stroke, 2009, Volume: 40, Issue:8

    Topics: Aged; Aspirin; Cerebral Infarction; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-U

2009
Evaluation of the effectiveness of sarpogrelate on the surrogate markers for macrovascular complications in patients with type 2 diabetes.
    Endocrine journal, 2012, Volume: 59, Issue:8

    Topics: Adiponectin; Adult; Aged; Ankle Brachial Index; Aspirin; Biomarkers; C-Reactive Protein; Carotid Int

2012
Sarpogrelate hydrochloride, a serotonin2A receptor antagonist, reduces albuminuria in diabetic patients with early-stage diabetic nephropathy.
    Diabetes research and clinical practice, 2002, Volume: 58, Issue:2

    Topics: Albuminuria; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Follow-Up Studies; Glycated

2002
A novel serotonin blocker, sarpogrelate, increases circulating adiponectin levels in diabetic patients with arteriosclerosis obliterans.
    Diabetes care, 2003, Volume: 26, Issue:8

    Topics: Adiponectin; Aged; Arteriosclerosis Obliterans; Diabetes Mellitus, Type 2; Female; Humans; Intercell

2003
Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes.
    Clinical journal of the American Society of Nephrology : CJASN, 2008, Volume: 3, Issue:2

    Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Arteriosclerosis Obliterans; Aspirin; Ch

2008

Other Studies

6 other studies available for sarpogrelate and Diabetes Mellitus, Type 2

ArticleYear
Effects of sarpogrelate on microvascular complications with type 2 diabetes.
    International journal of clinical pharmacy, 2019, Volume: 41, Issue:2

    Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Diabetic Neuropathie

2019
Sarpogrelate hydrochloride decreases cardio-ankle vascular index accompanied by increased serum lipoprotein lipase mass in type 2 diabetic patients.
    International heart journal, 2014, Volume: 55, Issue:4

    Topics: Aged; Ankle Brachial Index; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dose-Response Relation

2014
Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice.
    Endocrine research, 2009, Volume: 34, Issue:1-2

    Topics: Abdominal Fat; Adipocytes; Animals; Blood Glucose; Cell Count; Diabetes Mellitus, Type 2; Disease Mo

2009
Effect of sarpogrelate hydrochloride, a 5-HT2 blocker, on insulin resistance in Otsuka Long-Evans Tokushima fatty rats (OLETF rats), a type 2 diabetic rat model.
    Journal of cardiovascular pharmacology, 2004, Volume: 43, Issue:2

    Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Insulin; Insulin Resistan

2004
5-HT2A receptor antagonist increases circulating adiponectin in patients with type 2 diabetes.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2005, Volume: 16, Issue:6

    Topics: Adiponectin; Biomarkers; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelium, Vascular; Fe

2005
The effect of MCI-9042 on serotonin-induced platelet aggregation in type 2 diabetes mellitus.
    Thrombosis research, 1993, Apr-15, Volume: 70, Issue:2

    Topics: Adult; Aged; Collagen; Diabetes Mellitus, Type 2; Female; Humans; Ketanserin; Male; Middle Aged; Pla

1993